CN111094314A - 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 - Google Patents

含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 Download PDF

Info

Publication number
CN111094314A
CN111094314A CN201980004509.4A CN201980004509A CN111094314A CN 111094314 A CN111094314 A CN 111094314A CN 201980004509 A CN201980004509 A CN 201980004509A CN 111094314 A CN111094314 A CN 111094314A
Authority
CN
China
Prior art keywords
methyl
pharmaceutically acceptable
formula
compound
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980004509.4A
Other languages
English (en)
Other versions
CN111094314B (zh
Inventor
高鹏
曾蜜
谭松良
孙广俊
包如迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of CN111094314A publication Critical patent/CN111094314A/zh
Application granted granted Critical
Publication of CN111094314B publication Critical patent/CN111094314B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

公开一种作为JAK抑制剂的前药的通式(I)化合物及其医药组合物、使用所述化合物治疗炎症性疾病和肿瘤疾病的方法和用于制备所述化合物的方法和中间体。其中通式(I)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201980004509.4A 2018-08-15 2019-08-14 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 Active CN111094314B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810929378 2018-08-15
CN2018109293788 2018-08-15
PCT/CN2019/100554 WO2020034987A1 (zh) 2018-08-15 2019-08-14 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN111094314A true CN111094314A (zh) 2020-05-01
CN111094314B CN111094314B (zh) 2022-08-12

Family

ID=69525147

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980004509.4A Active CN111094314B (zh) 2018-08-15 2019-08-14 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用

Country Status (3)

Country Link
CN (1) CN111094314B (zh)
TW (1) TW202021977A (zh)
WO (1) WO2020034987A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112748203A (zh) * 2020-12-30 2021-05-04 苏州海科医药技术有限公司 一种创新药杰克替尼乳膏临床研究血浆样本中杰克替尼及zg0244浓度的生物分析方法
CN116249533A (zh) * 2020-07-17 2023-06-09 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290918A (zh) * 2015-11-24 2018-07-17 施万生物制药研发Ip有限责任公司 用于治疗胃肠发炎疾病的jak抑制剂化合物的前药
WO2018217700A1 (en) * 2017-05-23 2018-11-29 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of janus kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140357557A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2018165250A1 (en) * 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
EP3609903A1 (en) * 2017-05-23 2020-02-19 Theravance Biopharma R&D IP, LLC Thiocarbamate prodrugs of tofacitinib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290918A (zh) * 2015-11-24 2018-07-17 施万生物制药研发Ip有限责任公司 用于治疗胃肠发炎疾病的jak抑制剂化合物的前药
WO2018217700A1 (en) * 2017-05-23 2018-11-29 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of janus kinase inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249533A (zh) * 2020-07-17 2023-06-09 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
CN112748203A (zh) * 2020-12-30 2021-05-04 苏州海科医药技术有限公司 一种创新药杰克替尼乳膏临床研究血浆样本中杰克替尼及zg0244浓度的生物分析方法

Also Published As

Publication number Publication date
TW202021977A (zh) 2020-06-16
CN111094314B (zh) 2022-08-12
WO2020034987A1 (zh) 2020-02-20

Similar Documents

Publication Publication Date Title
CN109963842B (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
TWI751163B (zh) Ｆｇｆｒ４抑制劑、其製備方法和應用
CN111601804B (zh) 含氮杂芳类衍生物调节剂、其制备方法和应用
KR101982912B1 (ko) 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
CN111094314B (zh) 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
CN114163454A (zh) 含吡啶多环类衍生物抑制剂、其制备方法和应用
CN110698481A (zh) 杂芳基吡啶酮和氮杂-吡啶酮酰胺化合物
TWI580679B (zh) 雜芳基並嘧啶類衍生物、其製備方法和用途
US20230113478A1 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
WO2013097225A1 (en) Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors
JP2021525252A (ja) 三環式誘導体を含む阻害剤、その製造方法、及び使用
EP3498707A1 (en) Fgfr4 inhibitor and preparation method and use thereof
JP7446287B2 (ja) Ｆｇｆｒ４阻害剤及びその使用
EP4223754A1 (en) Compound as akt kinase inhibitor
TWI821559B (zh) 一種cd73抑制劑，其製備方法和應用
WO2020259703A1 (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN111825719A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
EP4245757A1 (en) Crystal form of free base of inhibitor containing bicyclic ring derivative and preparation method and application of crystal form
CN113004282B (zh) 取代的炔基杂环化合物
CN113493439B (zh) 取代的丙烯酰胺衍生物及其组合物及用途
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
EP4378943A1 (en) 8-oxo-3-azabicyclo[3.2.1]octane compound or salt thereof, and preparation method therefor and use thereof
WO2022171072A1 (zh) 一种二氢嘧啶类化合物、其制备方法及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant